$CNTB News

Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript

Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target

Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target

Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations - Slideshow

Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript

BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Connect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85%

Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?

Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target

Canaccord Genuity Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $6

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations - Slideshow